托珠单抗治疗巨细胞动脉炎复发时的糖皮质激素剂量与急性期反应物水平
该随机试验评估巨细胞动脉炎(GCA)复发时的泼尼松剂量及血清学指标。结果显示多数复发发生在仍使用泼尼松期间,且托珠单抗(TCZ)联合泼尼松组92%复发时C反应蛋白(CRP)正常,提示急性期反应物不能可靠指示复发。
要点
- 多数GCA复发发生于仍在接受泼尼松治疗的患者。
- TCZ联合泼尼松组复发时92%CRP正常,急性期反应物不可靠。
- 加用TCZ比单用泼尼松更早实现GCA病情控制。
核心结论
- 多数GCA复发发生在患者仍使用泼尼松时。
- 急性期反应物水平不能可靠指示接受TCZ联合泼尼松或单用泼尼松患者的复发。
- 加用TCZ有利于更早控制GCA。
研究设计与样本
- GCA患者随机分配至双盲接受TCZ 162 mg每周皮下注射+26周泼尼松减量、TCZ每两周+26周泼尼松减量、安慰剂+26周泼尼松减量或安慰剂+52周泼尼松减量。
- 结局指标为复发时泼尼松剂量、CRP水平和红细胞沉降率(ESR)。
主要发现
- 149例TCZ治疗患者中36例(24%)发生复发,其中23例(64%)仍在接受泼尼松(中位剂量2.0 mg/天)。
- 101例安慰剂+泼尼松治疗患者中59例(58%)发生复发,其中45例(76%)仍在接受泼尼松(中位剂量5.0 mg/天)。
- TCZ组9例(25%)和安慰剂组13例(22%)复发时泼尼松剂量>10 mg/天。
- 超过半数安慰剂+泼尼松治疗患者CRP升高但无复发。
临床怎么用
- 接受TCZ联合泼尼松或单用泼尼松治疗的GCA患者,不能仅凭CRP或ESR正常排除复发。
- 多数复发发生在泼尼松减量过程中,需结合临床综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to evaluate glucocorticoid dosages and serologic findings in patients with giant cell arteritis (GCA) flares. METHODS: Patients with GCA were randomly assigned to receive double-blind dosing with either subcutaneous tocilizumab (TCZ) 162 mg weekly plus 26-week prednisone taper (TCZ-QW + Pred-26), every-other-week TCZ plus 26-week prednisone taper (TCZ-Q2W + Pred-26), placebo plus 26-week prednisone taper (PBO + Pred-26), or placebo plus 52-week prednisone taper (PBO + Pred-52). Outcome measures were prednisone dosage, C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) at the time of flare. RESULTS: One hundred patients received TCZ-QW + Pred-26, 49 received TCZ-Q2W + Pred-26, 50 received PBO + Pred-26, and 51 received PBO + Pred-52. Of the 149 TCZ-treated patients, 36 (24%) experienced flare, 23 (64%) of whom were still receiving prednisone (median dosage 2.0 mg/day). Among 101 PBO + Pred-treated patients, 59 (58%) experienced flare, 45 (76%) of whom were receiving prednisone (median dosage 5.0 mg/day). Many flares occurred while patients were taking >10 mg/day prednisone: 9 (25%) in the TCZ groups and 13 (22%) in the placebo groups. Thirty-three flares (92%) in TCZ-treated groups and 20 (34%) in PBO + Pred-treated groups occurred with normal CRP levels. More than half of the PBO + Pred-treated patients had elevated CRP levels without flares. Benefits of the TCZ and prednisone combination over prednisone alone for remission induction were apparent by 8 weeks. CONCLUSION: Most GCA flares occurred while patients were still receiving prednisone. Acute-phase reactant levels were not reliable indicators of flare in patients treated with TCZ plus prednisone or with prednisone alone. The addition of TCZ to prednisone facilitates earlier GCA control.
引用
- Stone JH, Tuckwell K, Dimonaco S, et al. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol. 2019. PMID: 30835950. doi:10.1002/art.40876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。